About the VHIR
Here at the Vall d'Hebron Research Institute (VHIR) we promote biomedical research, innovation and teaching. Over 1,800 people are seeking to understand diseases today so the treatment can be improved tomorrow.
Research
We are working to understand diseases, to find out how they operate and to create better treatments for patients. Get to know about our groups and their lines of research.
People
People are the centre of the Vall d'Hebron Research Institute (VHIR). This is why we are bound by the principles of freedom of research, gender equality and professional attitudes that HRS4R promotes.
Clinical trials
Our work is not just basic or translational; we are leaders in clinical research. Enter and find about the clinical trials we are conducting and why we are a world reference in this field.
Progress
Our aim is to make the research carried out at the Vall d’Hebron Research Institute (VHIR) a driving force for transformation. How? By identifying new channels and solutions for the promotion of people's health and well-being.
Core facilities
We offer specialist support for researchers, internal and external alike, ranging from specific services to preparing complete projects. All this, from a perspective of quality and speed of response.
News
We offer you a gateway for staying up to date on everything going on at the Vall d’Hebron Research Institute (VHIR), from the latest news to future solidarity activities and initiatives that we are organising.
The Infection and Immunity in pediatric patients research group is a multidisciplinary pediatric research group made up of health professionals involved in translational research in the field of pediatric infectious diseases and immunodeficiencies, two related fields in terms of pathophysiology and clinical implications. It is a consolidated research group recognized by the AGAUR and is the only one with the accreditation of the Jeffrey Modell Foundation in research in the field of primary immunodeficiencies throughout the state.
The group was officially created in 2010, belongs to the area of Infectious Diseases and participates in the transversal programs of Advanced Translational Immunology and Rare Diseases and actively participates in national and international competitive projects, carries out multiple academic and industry-linked clinical trials and has increased the number and quality in recent years. In addition, it has its own laboratory specially dedicated to advanced immune studies.
IP: Jacques Gabriel Rivière, Pere Soler Palacín
IP: Jorgina Vila Soler, Pere Soler Palacín
IP: Pere Soler Palacín Collaborators: Antoni Soriano Arandes, Jorgina Vila Soler, Laura Batlle Masó, Natalia Ana Mendoza Palomar, Maria Espiau Guarner, Aurora Fernandez Polo, Núria Worner Tomasa, Laura Lopez Seguer, Miriam Gonzalez Amores, Susana Melendo Perez, Sonia Rodriguez Tello, Andrea Martín Nalda, Claudia Broto Cortes, Marie Antoinette Frick, Jacques Gabriel Rivière Funding agency: Agència Gestió Ajuts Universitaris i de Recerca Funding: 0.01 Reference: 2021 SGR 00441 Duration: 01/01/2022 - 30/06/2025
IP: Andres Antón Pagarolas Collaborators: Juliana Esperalba Esquerra, Jorgina Vila Soler, Yolima Cossio Gil, Rocío Rodrigo García, Tomàs Pumarola Suñé, Maria Espiau Guarner, Núria Worner Tomasa, Maria Piñana Moro, Ariadna Carsi Durall, Anna Creus Costa, Alejandra Gonzalez Sánchez, Cristina Andrés Vergés, Narcís Saubí Roca Funding agency: Instituto de Salud Carlos III Funding: 214170 Reference: PI22/00023 Duration: 01/01/2023 - 31/12/2025
IP: Roger Colobran Oriol Collaborators: Aina Aguiló Cucurull, Andrea Martín Nalda, Laura Batlle Masó Funding agency: Instituto de Salud Carlos III Funding: 159720 Reference: PI20/00761 Duration: 01/01/2021 - 30/06/2025
IP: Juan Jose Gonzalez Lopez Collaborators: Manuel Hernández González, Jose Angel Rodrigo Pendás, Maria Belén Viñado Perez, Aina Aguiló Cucurull, Alba Mir Cros, Albert Moreno Mingorance, Andrea Martín Nalda, Nuria Serre Delcor, Josep Roca Grande, Laura Batlle Masó Funding agency: Instituto de Salud Carlos III Funding: 123420 Reference: PI21/00132 Duration: 01/01/2022 - 30/06/2026
Funding has been obtained for 43 projects under the calls for Health R&D&I Projects, Health Technology Development, and Independent Clinical Research
The project, in which Vall d’Hebron participates, studied the Bimervax® vaccine in immunocompromised individuals and paediatric patients.
The study seeks to better understand blood disorders in children and young people, analyzing the role of immunological alterations to improve diagnosis and treatment.
